Shared on05 Sep 25
With no meaningful changes in Concord Biotech’s net profit margin or future P/E, the consensus analyst price target remains steady at ₹1840. What's in the News Announced annual dividend of INR 10.70 per share, payable in October 2025.
Shared on23 Apr 25
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on17 Apr 25
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on09 Apr 25
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on02 Apr 25Fair value Increased 10%
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on26 Mar 25
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on19 Mar 25Fair value Decreased 1.98%
AnalystConsensusTarget made no meaningful changes to valuation assumptions.